Annual report pursuant to Section 13 and 15(d)

Commitments And Contingencies (Details)

v3.19.1
Commitments And Contingencies (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Feb. 16, 2018
unit
$ / unit
Dec. 18, 2015
USD ($)
unit
Aug. 31, 2018
USD ($)
Nov. 30, 2017
$ / unit
Sep. 30, 2018
USD ($)
extension
Dec. 31, 2018
USD ($)
Oct. 31, 2017
Operating Leased Assets [Line Items]              
Noncontrolling interest ownership percentage by Noncontrolling Owners             10.00%
Rent expense           $ 41,749  
Rockville Office              
Operating Leased Assets [Line Items]              
Incentive to lessee           381,900  
Annual base rent         $ 161,671    
Annual rent increase (as a percent)         2.50%    
Period of abatement         12 months    
Lease term         10 years    
Number of optional extensions | extension         2    
Lease renewal term         5 years    
Karbinal Agreement | TRIS Pharma              
Operating Leased Assets [Line Items]              
Minimum quantity required | unit 70,000            
Make whole payment (in dollars per unit) | $ / unit 30            
Make whole payment     $ 934,300     1,281,525  
Accrued make whole payment           $ 700,000  
Zylera | Ulesfia Supply Agreement              
Operating Leased Assets [Line Items]              
Price (in dollars per unit) | $ / unit       58.84      
Management and handling fee (in dollars per unit) | $ / unit       3.66      
Management and handling fee annual price increase       10.00%      
Zylera | Ulesfia Supply Agreement | Lachlan Pharmaceuticals              
Operating Leased Assets [Line Items]              
Minimum quantity required | unit   20,000          
Long-term purchase commitment   $ 1,200,000          
Minimum royalty   $ 3,000,000          
Indemnification of post-acquisition losses, (as a percent)           50.00%